Ubaid Tanveer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ubaid Tanveer has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Johnathan R. Yarbro
Department of Medicine, Division of Hematology and Oncology, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN 38163, USA
2 shared publications - Laura M. Sipe
Department of Biology, University of Mary Washington , Fredericksburg, VA 22401
2 shared publications - Liza Makowski
Department of Microbiology, Immunology, and Biochemistry, College of Medicine, The University of Tennessee Health Science Center, Memphis, USA
2 shared publications - Margaret S. Bohm
Department of Microbiology, Immunology, and Biochemistry, College of Medicine, The University of Tennessee Health Science Center, Memphis, USA
2 shared publications - Mehdi Chaib
Preprint Club, University of Texas MD Anderson Cancer Center, Houston, USA
2 shared publications - Paul Glyndwr Thomas
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA
2 shared publications
Latest Publications
- Open Access
- 22 December 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (51) , eadd3231
Protein kinase C delta regulates mononuclear phagocytes and hinders response to immunotherapy in cancer
Mononuclear phagocytes (MPs) play a crucial role in tissue homeostasis; however, MPs also contribute to tumor progression and resistance to immune checkpoint blockade (ICB). Targeting MPs could be an effective strategy to enhance ICB efficacy. We report that protein kinase C delta (PKCδ), a serine/threonine kinase, is abundantly expressed by MPs in human and mouse tumors. PKCδ −/− mice displayed reduced tumor progression compared to wild types, with increased response to anti–PD-1. Tumors from PKCδ −/− mice demonstrated T H 1-skewed immune response including increased antigen presentation and T cell activation. Depletion of MPs in vivo altered tumor growth in control but not PKCδ −/− mice. Coinjection of PKCδ −/− M2-like macrophages with cancer cells into wild-type mice markedly delayed tumor growth and significantly increased intratumoral T cell activation compared to PKCδ +/+ controls. PKCδ deficiency reprogrammed MPs by activating type I and type II interferon signaling. Thus, PKCδ might be targeted to reprogram MPs to augment ICB efficacy.
- 22 December 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (51) , eadd3231
Open AccessProtein kinase C delta regulates mononuclear phagocytes and hinders response to immunotherapy in cancer
Mononuclear phagocytes (MPs) play a crucial role in tissue homeostasis; however, MPs also contribute to tumor progression and resistance to immune checkpoint blockade (ICB). Targeting MPs could be an effective strategy to enhance ICB efficacy. We report that protein kinase C delta (PKCδ), a serine/threonine kinase, is abundantly expressed by MPs in human and mouse tumors. PKCδ −/− mice displayed reduced tumor progression compared to wild types, with increased response to anti–PD-1. Tumors from PKCδ −/− mice demonstrated T H 1-skewed immune response including increased antigen presentation and T cell activation. Depletion of MPs in vivo altered tumor growth in control but not PKCδ −/− mice. Coinjection of PKCδ −/− M2-like macrophages with cancer cells into wild-type mice markedly delayed tumor growth and significantly increased intratumoral T cell activation compared to PKCδ +/+ controls. PKCδ deficiency reprogrammed MPs by activating type I and type II interferon signaling. Thus, PKCδ might be targeted to reprogram MPs to augment ICB efficacy.
- Open Access
- 21 January 2022
- Published by Elsevier in Cancer Letters
- Vol. 531, 98-108
PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8+ T cells in breast cancer
- 21 January 2022
- Published by Elsevier in Cancer Letters
- Vol. 531, 98-108
Open AccessPKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8+ T cells in breast cancer